Covid-19 vaccine candidate Gennova gets nod for human testing
Preliminary information released by the two companies on late stage trials of their vaccines show that they have an efficacy of around 94-95 per cent, which means they have the potential to cut down symptomatic Covid-19 cases by up to 95 per cent among those vaccinated. December 12, 2020 2:21:08 am
Gennova’s candidate, known as HGCO19, is “stable” at 2°C to 8°C for two months, according to the Ministry of Science and Technology. (Reuters/Representational)
The Drugs Controller General of India (DCGI) has given Pune-headquartered Gennova Biopharmaceuticals the green light to start early- to mid-stage human testing of its Covid-19 vaccine candidate. If successful, the candidate may be the first indigenously developed vaccine using mRNA technology that could potentially use India’s existing cold chain capacity.
Sources said GST entities that had not filed their GSTR-3B returns for over six months were first issued the cancellation notices and, then, their registrations were cancelled in accordance with the standard operating procedure.
Split plan scrapped, EPFO to credit interest by month-end in one go indianexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indianexpress.com Daily Mail and Mail on Sunday newspapers.
Require panel to review allocation of legislative powers between Centre & states in Schedule VII of Constitution, said 15th Finance Commission Chairman NK Singh.